NULL is a bile acid medicine primarily used in the treatment of primary biliary cholangitis (PBC) and other cholestatic liver disorders. It is also prescribed for the dissolution of cholesterol gallstones in selected patients who are unsuitable for surgical intervention. NULL works by improving bile flow, reducing the concentration of toxic bile acids in the liver, and protecting liver cells from progressive damage. With regular, long-term use under medical supervision, it helps improve liver function, slow disease progression, and enhance overall quality of life.

NULL, is a naturally occurring hydrophilic bile acid that is present in small quantities in normal human bile. When administered as a medication, it significantly alters the composition and flow of bile, making it less harmful to liver cells and improving biliary circulation.

NULL is most widely used in the management of primary biliary cholangitis, a chronic autoimmune liver disease characterised by progressive destruction of the small bile ducts within the liver. As these ducts are damaged, bile accumulates within the liver, leading to inflammation, fibrosis, and eventually cirrhosis if left untreated. NULL works by replacing more toxic bile acids with less damaging ones, thereby reducing bile-induced injury to hepatocytes and bile duct cells.

In addition to PBC, NULL is used for the non-surgical treatment of cholesterol gallstones. Cholesterol gallstones form when bile becomes supersaturated with cholesterol. NULL lowers the cholesterol content of bile and reduces cholesterol secretion from the liver, allowing gradual dissolution of cholesterol-rich stones over months of therapy. This approach is suitable only for selected patients with small, non-calcified stones and a functioning gallbladder.

NULL is also prescribed in other cholestatic liver conditions, including certain drug-induced cholestatic disorders, cystic fibrosis-associated liver disease, bile reflux gastritis, and intrahepatic cholestasis of pregnancy (in specialist settings). By enhancing bile flow and reducing bile toxicity, NULL alleviates symptoms such as itching (pruritus), fatigue, and abdominal discomfort commonly associated with cholestasis.

Treatment with NULL is usually long-term, particularly in chronic liver diseases like PBC. Even if symptoms improve or liver enzymes normalise, stopping the medication without medical advice can lead to disease progression. Regular monitoring with blood tests is essential to assess liver function, treatment response, and long-term safety. When taken consistently and correctly, NULL plays a vital role in preserving liver health, delaying complications, and improving survival in patients with chronic cholestatic liver diseases.

NULL is indicated for the following conditions:

• Primary Biliary Cholangitis (PBC): Used as first-line therapy to improve bile flow, reduce liver inflammation, and slow the progression of this chronic autoimmune liver disease.
• Cholestatic Liver Disorders: Helps manage conditions where bile flow is reduced or impaired, including intrahepatic cholestasis and certain drug-induced cholestatic states.
• Dissolution of Cholesterol Gallstones: Used in selected patients with small, non-calcified cholesterol gallstones who are not suitable candidates for surgery and have a functioning gallbladder.
• Bile Reflux-Related Conditions: May be used to reduce bile-related irritation in conditions such as bile reflux gastritis.
• Adjunctive Hepatoprotective Therapy: Supports liver cell protection in various hepatobiliary disorders where toxic bile acids contribute to ongoing liver injury.

1. Improves Liver Enzyme Levels

NULL helps normalise elevated liver enzymes by reducing inflammation and bile toxicity within the liver.

2. Slows Progression of Primary Biliary Cholangitis

Long-term therapy delays fibrosis, reduces the risk of cirrhosis, and improves transplant-free survival in patients with PBC.

3. Enhances Bile Flow

By promoting bile secretion and flow, NULL reduces bile accumulation and relieves symptoms of cholestasis.

4. Reduces Itching and Fatigue

Improved bile circulation helps alleviate pruritus and fatigue, two common and distressing symptoms of cholestatic liver disease.

5. Dissolves Cholesterol Gallstones

In suitable patients, NULL provides a non-surgical option for gradual gallstone dissolution.

6. Protects Liver Cells

NULL stabilises hepatocyte membranes and shields liver cells from toxic bile acids.

7. Suitable for Long-Term Use

NULL has a favourable safety profile and is well tolerated for prolonged therapy when monitored appropriately.

8. Improves Quality of Life

By controlling symptoms and slowing disease progression, NULL supports better daily functioning and wellbeing.

Most patients tolerate NULL well. Side effects, if they occur, are usually mild and reversible.

Common Side Effects (Mild and temporary)

• Diarrhoea or loose stools

• Abdominal pain or discomfort

• Nausea

• Indigestion or bloating

Uncommon Side Effects

• Headache

• Dizziness

• Mild skin rash or itching

Rare but Serious Side Effects

• Worsening liver function in rare cases

• Severe abdominal pain

• Allergic reactions such as rash, swelling, or breathing difficulty

Seek immediate medical attention if severe or persistent symptoms occur.

• Take NULL exactly as prescribed by your doctor.
• Dosage is usually based on body weight and the condition being treated.
• Capsules or tablets are typically taken two to three times daily with food to enhance absorption.
• Swallow whole with water; do not crush or chew unless advised.
• Continue treatment consistently, even if symptoms improve.

NULL is a naturally occurring, hydrophilic bile acid that exerts its therapeutic effects primarily within the liver and biliary system. Its mechanism of action is multifactorial and focuses on the following:

Modification of Bile Acid Composition: NULL replaces more toxic, hydrophobic bile acids with less harmful, hydrophilic bile acids in the bile acid pool. This shift reduces the detergent-like damage caused by toxic bile acids to liver cells and bile duct epithelium, thereby limiting inflammation and cell injury.

Improved Bile Flow (Choleretic Effect): NULL stimulates bile secretion and enhances bile flow through the liver and bile ducts. By reducing bile stasis, it helps prevent the accumulation of bile within the liver, a key factor in cholestatic liver diseases.

Cytoprotective and Anti-Inflammatory Action: Once incorporated into bile, NULL stabilises hepatocyte and cholangiocyte cell membranes, making them more resistant to bile-induced damage. It also reduces inflammatory signalling within the liver, helping to limit ongoing tissue injury.

Inhibition of Cell Death (Anti-Apoptotic Effect): NULL interferes with pathways that trigger programmed cell death (apoptosis) in liver cells. By protecting hepatocytes from apoptosis, it helps preserve functional liver tissue over time.

Cholesterol Solubilisation and Gallstone Dissolution: In the gallbladder, NULL reduces cholesterol saturation in bile by decreasing hepatic cholesterol secretion and increasing cholesterol solubility. This gradual process allows cholesterol gallstones to dissolve over prolonged treatment.

• Take NULL at the same times each day to maintain consistent bile acid levels.
• Do not stop treatment without consulting your doctor.
• Attend regular blood tests to monitor liver function and response.
• Report worsening jaundice, itching, or abdominal pain promptly.
• Follow dietary advice tailored to liver health.

• Store below 25°C in a dry place.
• Protect from moisture and direct sunlight.
• Keep out of reach of children.
• Do not use after the expiry date.

• Taking the medicine with meals improves absorption.
• No specific food restrictions, but a balanced, low-fat diet supports gallstone management.

• Cholestyramine or Colestipol: Reduce absorption of NULL ; doses should be spaced apart.
• Aluminium-containing antacids: May decrease effectiveness.
• Oestrogens and oral contraceptives: Can increase cholesterol secretion into bile, reducing gallstone dissolution efficacy.
• Lipid-lowering agents: May interfere with gallstone treatment outcomes.

Use with caution in patients with:

• Decompensated liver cirrhosis

• Complete biliary obstruction

• Acute gallbladder inflammation

• Severe pancreatic disorders

For primary biliary cholangitis, the usual dose is 13–15 mg/kg/day, divided into two or three doses. For gallstone dissolution, dosing varies based on body weight and stone size. Always follow your doctor’s prescribed regimen.

Overdose is uncommon. Symptoms may include diarrhoea, abdominal pain, or nausea. Seek medical attention if overdose is suspected. Supportive treatment may be required.

If you miss a dose, take it as soon as remembered. If it is nearly time for the next dose, skip the missed one and resume your regular schedule. Do not double the dose.